Cipla gets EIR from USFDA for API manufacturing facility in Bangalore

09 May 2020 Evaluate

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at API manufacturing facility in Bommasandra, Bangalore. The agency had conducted inspection from January 20, 2020 to January 24, 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1347.65 -10.15 (-0.75%)
27-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1738.10
Dr. Reddys Lab 1287.20
Cipla 1347.65
Zydus Lifesciences 922.50
Lupin 2301.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×